Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

Abstract: Methods and hydrogen sulfide (H2S) detecting apparatuses comprising a single reaction chamber defining a first volume, a single trapping chamber positioned adjacent to the reaction chamber defining a second volume, and an H2S-permeable membrane positioned between and separating the reaction chamber and the of trapping chamber, wherein the first volume is greater than the second volume.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

Abstract: This disclosure describes the use of plasma hydrogen sulfide metabolites as biomarkers for Rheumatoid arthritis, as well as the potential use of these metabolites as therapeutic efficacy targets.

Abstract: The disclosed invention is directed to devices, therapeutics and methods of diagnosing and treating cardio vascular disease in a patient comprising measuring plasma levels of one of free sulfide, acid labile sulfide (ALS), bound sulfane sulfur (BSS), total sulfide metabolites, and some combination thereof, diagnosing, based on plasma levels, the patient with cardio vascular disease, and administering a therapeutically effective dose of a pharmaceutical composition to the patient. According to a further embodiment, the patient is diagnosed with cardio vascular disease if the patient has a polymorphism in a cystathionine gamma-lyase gene but not a cystathionine-beta-synthase gene. According to a further embodiment, the patient is diagnosed with peripheral atrial disease if the patient is African American and the plasma BSS level is significantly lower than an average control plasma BSS level.

Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.

Abstract: A method of treating neuropathy in a subject, the method comprising identifying a subject who has neuropathy; and administering to the subject a pharmaceutical composition comprising one of inorganic nitrite and a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.

Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.

Abstract: Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.

Abstract: CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

Abstract: CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.

Abstract: Hydrogen sulfide (H2S) levels in plasma are useful in diagnosing cardiovascular disease. The ratio of H2S to NO in plasma is useful in diagnosing peripheral artery disease.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).